Literature DB >> 1673146

Class II MHC-restricted T cell determinants processed from either endosomes or the cytosol show similar requirements for host protein transport but different kinetics of presentation.

C J Hackett1, J W Yewdell, J R Bennink, M Wysocka.   

Abstract

We have studied the role of APC protein transport in presentation of class II MHC-restricted T cell determinants of influenza virus glycoproteins that have distinct Ag processing requirements. Two I-Ed-restricted epitopes were analyzed: hemagglutinin (HA) 111-119, which is processed by the exogenous/endocytic pathway, and neuraminidase (NA) 79-93, which has a requirement for cytosolic processing. NA 79-93 is presented from infectious but not non-replicative virus under ordinary conditions. This requirement for viral biosynthesis could be bypassed by using a soluble inhibitor of NA,2,3-dehydro-2-deoxy-N-acetyl neuraminic acid (DDAN), to facilitate cytosolic introduction of virus. APC exposed to UV virus/DDAN present HA and NA determinants derived directly from proteins of the input virus particles. This allows presentation of both endocytically and cytosolically processed epitopes in the same experiment using noninfectious virus. The inhibitor brefeldin A (BFA) was used to interrupt host protein transport at various times relative to virus/DDAN addition. We observed that BFA added simultaneously with virus blocked recognition of NA 79-93 but not HA 111-119. This distinction was found to be based upon different expression kinetics of the HA and NA determinants. Expression of NA 79-93 required 6 to 9 h, whereas HA 111-119 was presented by 1 h after Ag addition. When APC were incubated with BFA at intervals before virus addition, presentation of HA 111-119 was also blocked as a function of time. Data indicate that about 5 h of BFA treatment is needed to deplete host protein pools required for presentation of I-Ed-restricted T cell determinants processed from either endosomes or the cytosol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673146

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Presentation of a cytosolic antigen by major histocompatibility complex class II molecules requires a long-lived form of the antigen.

Authors:  M Guéguen; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 2.  Influenza vaccine responses in older adults.

Authors:  Janet E McElhaney
Journal:  Ageing Res Rev       Date:  2010-11-03       Impact factor: 10.895

3.  Detection and quantification of CD4(+) T cells with specificity for a new major histocompatibility complex class II-restricted influenza A virus matrix protein epitope in peripheral blood of influenza patients.

Authors:  T Linnemann; G Jung; P Walden
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01

5.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

6.  Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain.

Authors:  M J Bijlmakers; P Benaroch; H L Ploegh
Journal:  EMBO J       Date:  1994-06-01       Impact factor: 11.598

7.  Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition.

Authors:  R S van Binnendijk; C A van Baalen; M C Poelen; P de Vries; J Boes; V Cerundolo; A D Osterhaus; F G UytdeHaag
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

8.  Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants.

Authors:  D J Kittlesen; L R Brown; V L Braciale; J P Sambrook; M J Gething; T J Braciale
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.